Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura.
Völker LA, Kaufeld J, Miesbach W, Brähler S, Reinhardt M, Kühne L, Mühlfeld A, Schreiber A, Gaedeke J, Tölle M, Jabs WJ, Özcan F, Markau S, Girndt M, Bauer F, Westhoff TH, Felten H, Hausberg M, Brand M, Gerth J, Bieringer M, Bommer M, Zschiedrich S, Schneider J, Elitok S, Gawlik A, Gäckler A, Kribben A, Schwenger V, Schoenermarck U, Roeder M, Radermacher J, Bramstedt J, Morgner A, Herbst R, Harth A, Potthoff SA, von Auer C, Wendt R, Christ H, Brinkkoetter PT, Menne J. Völker LA, et al. Blood Adv. 2020 Jul 14;4(13):3085-3092. doi: 10.1182/bloodadvances.2020001973. Blood Adv. 2020. PMID: 32634236 Free PMC article.
ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP.
Völker LA, Kaufeld J, Miesbach W, Brähler S, Reinhardt M, Kühne L, Mühlfeld A, Schreiber A, Gaedeke J, Tölle M, Jabs WJ, Özcan F, Markau S, Girndt M, Bauer F, Westhoff TH, Felten H, Hausberg M, Brand M, Gerth J, Bieringer M, Bommer M, Zschiedrich S, Schneider J, Elitok S, Gawlik A, Gäckler A, Kribben A, Schwenger V, Schoenermarck U, Roeder M, Radermacher J, Bramstedt J, Morgner A, Herbst R, Harth A, Potthoff SA, von Auer C, Wendt R, Christ H, Brinkkoetter PT, Menne J. Völker LA, et al. Blood Adv. 2020 Jul 14;4(13):3093-3101. doi: 10.1182/bloodadvances.2020001987. Blood Adv. 2020. PMID: 32634237 Free PMC article.
Caplacizumab: frequent local skin reactions.
Kaufeld J, Brinkkoetter PT, Schreiber A, Jabs WJ, Bieringer M, Bruck H, Menne J, Völker LA. Kaufeld J, et al. Ann Hematol. 2021 Dec;100(12):3051-3052. doi: 10.1007/s00277-020-04260-7. Epub 2020 Sep 30. Ann Hematol. 2021. PMID: 32997190 Free PMC article. No abstract available.
Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura.
Völker LA, Kaufeld J, Balduin G, Merkel L, Kühne L, Eichenauer DA, Osterholt T, Hägele H, Kann M, Grundmann F, Kolbrink B, Schulte K, Gäckler A, Kribben A, Boss K, Potthoff SA, Rump LC, Schmidt T, Mühlfeld AS, Schulmann K, Hermann M, Gaedeke J, Sauerland K, Bramstedt J, Hinkel UP, Miesbach W, Bauer F, Westhoff TH, Bruck H, Buxhofer-Ausch V, Müller TJ, Wendt R, Harth A, Schreiber A, Seelow E, Tölle M, Gohlisch C, Bieringer M, Geuther G, Jabs WJ, Fischereder M, von Bergwelt-Baildon A, Schönermarck U, Knoebl P, Menne J, Brinkkoetter PT; German TTP-Study Group. Völker LA, et al. J Thromb Haemost. 2023 Mar;21(3):559-572. doi: 10.1016/j.jtha.2022.11.010. Epub 2022 Dec 22. J Thromb Haemost. 2023. PMID: 36696206 Free article.
Alternate-day dosing of caplacizumab for immune-mediated thrombotic thrombocytopenic purpura.
Kühne L, Kaufeld J, Völker LA, Wendt R, Schönermarck U, Hägele H, Osterholt T, Eichenauer DA, Bieringer M, von Bergwelt-Baildon A, Fischereder M, Buxhofer-Ausch V, Menne J, Brinkkoetter PT, Knöbl P. Kühne L, et al. Among authors: volker la. J Thromb Haemost. 2022 Apr;20(4):951-960. doi: 10.1111/jth.15637. Epub 2022 Jan 23. J Thromb Haemost. 2022. PMID: 35000278 Free article.
73 results